司库奇尤单抗治疗斑块型银屑病合并肾功能不全1例

doi:10.16138/j.1673-6087.2025.03.12

摘要/Abstract

摘要：

男性患者46岁，既往因痛风和高血压导致尿毒症，接受肾移植术，目前合并肾功能不全，长期口服麦考酚钠肠溶片540 mg，每日2次、他克莫司（早1 mg，晚2 mg）和甲泼尼龙4 mg抗排异。口服硝苯地平控释片30 mg，每日2次控制高血压。抑郁症病史3年，口服曲唑酮50 mg，每日2次，富马酸喹硫平200 mg，每日2次；2022年12月新型冠状病毒感染治愈，2023年1月确诊斑块状银屑病，口服抗过敏药物和外用激素类对症治疗效果不佳。本次入院给予司库奇尤单抗300 mg治疗后，银屑病面积与严重程度指数（psoriasis area and severity index， PASI）评分及皮肤病生活质量指数(dermatology life quality index, DLQI)评分明显改善，耐受性好，为银屑病合并肾功能不全患者治疗提供借鉴。

关键词: 斑块状银屑病, 肾功能不全, 司库奇尤单抗

Abstract:

The 45-year-old male patient had uremia due to gout and hypertension in the past and underwent kidney transplantation, currently complicated with renal insufficiency. To prevent rejection, the patient administrated mycopherol sodium enteric-covered tablets 540 mg，twice a day, tacrolimus 1 mg in the morning and 2 mg in the evening and methylprednisolone 4 mg orally for long-term. Nifedipine controlled release tablets (30 mg, twice a day) were used for hypertension. Following a diagnosis of depression 3 years ago， medication was commenced with trazodone (50 mg, twice a day) and quetiapine fumarate (200 mg, twice a day) orally. The patient got novel coronavirus infection and was cured in December 2022. The plaque psoriasis was diagnosed in January 2023, and the treatment effect of oral anti-allergy drugs and topical hormone symptomatic treatment was not good for him. After being admitted to the hospital and receiving treatment of secukinumab 300 mg, psoriasis area and severity index (PASI) score and dermatology life quality index(DLQI) score of the patient were significantly improved, and he also showed well tolerated. The treatment of the case provides reference for the similar patients with psoriasis complicated with renal insufficiency.

Key words: Plaque psoriasis, Renal insufficiency, Secukinumab

中图分类号:

R593.3

周婷, 解沛涛, 张亮. 司库奇尤单抗治疗斑块型银屑病合并肾功能不全1例[J]. 内科理论与实践, 2025, 20(03): 259-261.

ZHOU Ting, XIE Peitao, ZHANG Liang. Secuchiumab in treatment of plaque psoriasis complicated with renal insufficiency: a case analysis[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(03): 259-261.

图/表 2

参考文献 15

[1]	张学军, 郑捷. 皮肤性病学[M]. 9版. 北京: 人民卫生出版社, 2018:133.
[2]	Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study[J]. BMJ, 2020,369:m1590.
[3]	华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7):573-625.
[4]	Torales J, Echeverría C, Barrios I, et al. Psychodermatological mechanisms of psoriasis[J]. Dermatol Ther, 2020, 33(6):e13827.
[5]	Novartis Pharma Schweiz AG. 司库奇尤单抗注射液说明书(2022年版)[EB/OL]. 2022. https://www.novartis.com.cn/products/pharmaceuticals.
[6]	Papp KA, Gooderham M, Lynde C, et al. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry[J]. Arch Dermatol Res, 2024, 316(7):362.
[7]	Shi X, Jin L, Dang E, et al. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms[J]. J Invest Dermatol, 2011, 131(12):2401-2408. doi: 10.1038/jid.2011.222 pmid: 21796151
[8]	Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis[J]. Med Res Rev, 2014, 34(2):438-454. doi: 10.1002/med.21291 pmid: 23722817
[9]	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis[J]. Chin Med J (Engl), 2020, 133(22):2665-2673.
[10]	Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies[J]. Drug Discov Today, 2006 11(1-2):81-88. doi: 10.1016/S1359-6446(05)03638-X pmid: 16478695
[11]	Karataş A, Gerçek AN, Öz B, et al. The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis[J]. Eur J Rheumatol, 2020, 7(4):169-172.
[12]	Ikuma D, Oguro M, Hoshino J, et al. Efficacy of secukinumab for plaque psoriasis in a patient on hemodialysis[J]. CEN Case Rep, 2020, 9(1):55-58.
[13]	Mukai M, Kurihara Y, Ito Y, et al. Successful treatment with secukinumab of three psoriatic patients undergoing dialysis[J]. J Dermatol, 2020, 47(1):e26-e28. doi: 10.1111/1346-8138.15132
[14]	Pizzatti L, Mugheddu C, Sanna S, et al. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab[J]. Dermatol Ther, 2020, 33(3):e13348.
[15]	Cao Z, Liu Z, Zhu X, et al. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis[J]. Ren Fail, 2022, 44(1):826-830. doi: 10.1080/0886022X.2022.2073893 pmid: 35546261